Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,262 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Interventions: QR-313, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 4 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 4
States / cities: Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more

Conditions: HIV Prevention
Interventions: Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel, Universal HEC Placebo Gel Formulation; Drug
Lead sponsor: Ian McGowan; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 2
States / cities: Los Angeles, California • Pittsburgh, Pennsylvania

Conditions: Peanut Allergy
Interventions: walnut powder; Drug
Lead sponsor: Jonathan Spergel; Other
Eligibility: 6 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vulvodynia
Interventions: Placebo oral capsule, Gabapentin; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older · Female only
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Rochester, New York • Memphis, Tennessee

Conditions: Tourette Syndrome, Chronic Tic Disorder
Interventions: Active Oral Orthotic Treatment, Placebo Oral Orthotic Treatment; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 7 Years to 25 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Ad26.RSV.preF 5*10^10 vp, Ad26.RSV.preF 1*10^11 vp, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 60 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Osteochondrodysplasia
Interventions: SAR442501, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Pain
Interventions: Real acupuncture, Sham acupuncture, VGAIT, VGAIT control; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC 0070-0002-0182, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Evansville, Indiana • Madison, Wisconsin

Conditions: Primary Hypercholesterolemia
Interventions: P-OM3, Placebo; Drug
Lead sponsor: Provident Clinical Research; Other
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Smoking Cessation
Interventions: placebo, Varenicline Tartarate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Advanced Or Metastatic Merkel Cell Carcinoma
Interventions: IFx-Hu2.0, Placebo, Pembrolizumab; Drug
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 15 more

Conditions: Chronic Graft-versus-host Disease
Interventions: Itacitinib, Placebo, Methylprednisolone, Prednisone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more

Conditions: Renal Transplantation, Mesenchymal Stem Cells
Interventions: Mesenchymal Stromal Stem Cells (MSCs) Infusion, Normal Saline (Placebo) Infusion; Biological · Other
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Migraine Prophylaxis
Interventions: E2007, Placebo; Drug · Other
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Oceanside, California • Santa Monica, California • Tampa, Florida + 6 more

Conditions: PTSD, Sleep Disorders
Interventions: prazosin, placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Loma Linda, California • Long Beach, California • Palo Alto, California + 12 more

Conditions: Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions: Darbepoetin alfa, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 2,549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 277
States / cities: Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more

Conditions: Chronic Pancreatitis, Exocrine Pancreatic Insufficiency
Interventions: Placebo, EUR-1008 (APT-1008) High Dose, EUR-1008 (APT-1008) Low Dose; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 6 more

Conditions: Type 2 Diabetes Mellitus, Hypertension
Interventions: Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT); Drug · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Cobimetinib, Paclitaxel, Placebo, Atezolizumab, Nab-Paclitaxel; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 11
States / cities: Jacksonville, Florida • Miami, Florida • Orlando, Florida + 8 more

Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 87
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more

Conditions: Cow's Milk Allergy
Interventions: Baked non-fat cow's milk powder, Placebo: Tapioca Powder; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Drug Addiction
Interventions: Within-subjects (MDMA), Within-subjects (oxytocin), Within-subjects (placebo); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 35 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nicotine Dependence
Interventions: Belsomra, Placebo, Methylphenidate; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally

Walnut Oral Immunotherapy for Tree Nut Allergy

A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response

Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

A First-in-human Single and Repeated Dose Escalation Study of SAR442501 in Healthy Adults Subjects

Mechanistic Studies on Video-guided Acupuncture Imagery Treatment of Pain

Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers

Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia

Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

Efficacy and Safety Study of E2007 in Migraine Prophylaxis

Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Baked Milk Oral Immunotherapy for Cow's Milk Allergy

Effects of MDMA on Social and Emotional Processing

Orexin s Role in the Neurobiology of Substance Use Disorder